ArticleInternational journal of nanomedicine2025
Cholesterol-Rich Antibiotic-Loaded Liposomes as Efficient Antimicrobial Therapeutics.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Engineering Stability: Cholesterol-Modulated Liposome Response to Physical and Chemical Stressors for Enhanced Antimicrobial Activity.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Liposome drug delivery strategies: state-of-the-art for combating bacterial biofilms.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Liposomal antibiotics have demonstrated higher bacteriostatic and bactericidal activities than free drugs. In this study, we investigated the effects of cholesterol (Chol) content of liposomes, liposome concentration, and surface coating with polyethylene glycol (PEG) on the antimicrobial activity of moxifloxacin (MOX) liposomes against Methods: MOX-liposome compositions with increasing Chol content were evaluated for their susceptibility to planktonic Results-Discussion: All liposomes had nano-dimensions ranging in diameter from 92nm to 114nm, with zeta-potential values from -2.30mV to -4.50mV. Planktonic bacteria and established biofilms are significantly more susceptible to MOX-liposomes with higher Chol-content than other liposome-types, and the same MOX dose encapsulated in 10 times higher lipids demonstrated higher antimicrobial activity. Coating the MOX liposomes with PEG did not affect their activity. Flow cytometry showed higher binding of Chol-rich liposomes to bacteria, explaining the higher antimicrobial activity. Interestingly, the integrity of calcein-loaded Chol-rich liposomes was much lower than that of liposomes with low or no Chol during incubation with various strains of Conclusion: The current in vitro and in vivo findings demonstrated the potential of PEGylated and Chol-rich liposomal antibiotics as highly efficient therapeutics for the treatment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.